RetroSense Therapeutics
RetroSense Therapeutics (Michigan, USA) is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions. RetroSense’s approach creates photosensitivity in retinal ganglian cells via channelrhodopsin-2 expression restoring vision irrespective of which gene defect is responsible for vision loss. The company has successfully finished Ph1 clinical trials. Allergan (NYSE: AGN) acquired RetroSense Therapeutics in 2016 for a total consideration of $555M (including milestone payments).